WallStSmart

Cigna Corp (CI)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cigna Corp generates 4309% more annual revenue ($277.89B vs $6.30B). EW leads profitability with a 17.4% profit margin vs 2.3%. CI appears more attractively valued with a PEG of 0.82. CI earns a higher WallStSmart Score of 68/100 (B-).

CI

Strong Buy

68

out of 100

Grade: B-

Growth: 6.7Profit: 6.0Value: 9.3Quality: 4.8
Piotroski: 2/9

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 6.0Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CIUndervalued (+79.8%)

Margin of Safety

+79.8%

Fair Value

$1364.02

Current Price

$281.98

$1082.04 discount

UndervaluedFair: $1364.02Overvalued
EWUndervalued (+69.8%)

Margin of Safety

+69.8%

Fair Value

$262.87

Current Price

$83.20

$179.67 discount

UndervaluedFair: $262.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CI5 strengths · Avg: 8.6/10
P/E RatioValuation
12.0x10/10

Attractively priced relative to earnings

Market CapQuality
$74.83B9/10

Large-cap with strong market position

PEG RatioValuation
0.828/10

Growing faster than its price suggests

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
29.1%8/10

Earnings expanding 29.1% YoY

EW2 strengths · Avg: 9.0/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

CI3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

Profit MarginProfitability
2.3%3/10

2.3% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EW3 concerns · Avg: 3.0/10
PEG RatioValuation
2.074/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.4x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : CI

The strongest argument for CI centers on P/E Ratio, Market Cap, PEG Ratio. PEG of 0.82 suggests the stock is reasonably priced for its growth.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : CI

The primary concerns for CI are Revenue Growth, Profit Margin, Piotroski F-Score. Thin 2.3% margins leave little buffer for downturns.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.4x leaves little room for execution misses.

Key Dynamics to Monitor

CI profiles as a value stock while EW is a growth play — different risk/reward profiles.

EW carries more volatility with a beta of 0.94 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

CI generates stronger free cash flow (864M), providing more financial flexibility.

Bottom Line

CI scores higher overall (68/100 vs 61/100). EW offers better value entry with a 69.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cigna Corp

HEALTHCARE · HEALTHCARE PLANS · USA

Cigna is an American multinational managed healthcare and insurance company based in Bloomfield, Connecticut. Its insurance subsidiaries are major providers of medical, dental, disability, life and accident insurance and related products and services, the majority of which are offered through employers and other groups (e.g. governmental and non-governmental organizations, unions and associations).

Visit Website →

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?